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http://dx.doi.org/10.1016/j.jds.2012.0Abstract Previous studies have used both systemic and topical 5-aminolevulinic acid (ALA)-
mediated photodynamic therapy (PDT) to treat oral precancers including oral leukoplakia
(OL), oral erythroleukoplakia (OEL), and oral verrucous hyperplasia (OVH) as well as oral
cancers including oral verrucous carcinoma (OVC) and oral squamous cell carcinoma (OSCC).
Systemic ALA-PDT has been used to treat oral dysplastic lesions and oral cancers with prom-
ising clinical outcomes. The efficacy of a regular topical ALA-PDT (fluence rate, 100 mW/
cm2; light dose, 100 J/cm2) was tested on an extensive buccal OVC and an enhanced topical
ALA-PDT (fluence rate, 200 mW/cm2; light dose, 200 J/cm2) on an early-invasive OSCC;
complete regression of the carcinomas was demonstrated after 28 and 18 PDT treatments,
respectively. Several previous studies showed relatively good outcomes for OL lesions treated
with topical ALA-PDT. However, it was found that the regular topical ALA-PDT is very effective
for OVH and OEL lesions but less so for OL lesions. Better PDT outcomes are significantly asso-
ciated with OVH and OEL lesions with smaller size, pink to red color, epithelial dysplasia, or
thinner surface keratin layer. Moreover, the thicker surface keratin layer on the OL lesions
is responsible for the relatively poorer PDT outcomes for OL lesions. In addition, both lightof Dentistry, National Taiwan University Hospital, No. 1, Chang-Te Street, Taipei 10048, Taiwan.
.tw (C.-P. Chiang).
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308 H.-M. Chen et alemitting diode light- and laser light-mediated topical ALA-PDTs are comparative treatment
modalities for OVH and OEL lesions. Methotrexate- or vitamin D3-preconditioned prostate or
skin carcinoma cells can accumulate more intracellular protoporphyrin IX, resulting in an
increased killing of these preconditioned cells by subsequent ALA-PDT. Because chemotherapy
can help destroy carcinoma cells and tumor-associated vasculatures and cryotherapy pretreat-
ment may help the diffusion of ALA into lesional epithelial cells, the chemotherapy or
cryotherapy-combined topical ALA-PDT may be a new effective PDT alternative for treatment
of oral precancers and cancers. It is concluded that topical ALA-PDT using either light emitting
diode or laser light is very effective for OVH and OEL lesions but is relatively less effective for
OL lesions. If OVC or early-invasive OSCC has no concurrent regional or distant metastasis,
regular or enhanced topical ALA-PDT may have a high potential to treat these two particular
kinds of oral cancer. A large-scale human clinical trial is needed to evaluate the efficacies
of drug-preconditioned topical ALA-PDT and chemotherapy or cryotherapy-combined topical
ALA-PDT on oral precancers, OVC and early-invasive OSCC in the near future.
Copyright ª 2012, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.Introduction
Oral squamous cell carcinoma (OSCC) is the most frequent
malignant tumor of the oral cavity.1 In Taiwan, oral cancers
rank as the sixth most prevalent cancer in both genders and
account for the fourth most common cancers in males.2
Although there have been great advances in diagnosis and
treatment of OSCC in recent years, the 5-year survival rate
for advanced oral cancer patients has remained approxi-
mately 20%.3 Oral precancerous lesions are even more
prevalent than oral cancers. Without further interventions,
a part of these oral precancerous lesions finally transform
into oral cancers. Therefore, one of the best strategies to
prevent the occurrence of oral cancer is to treat the oral
cancer at its precancerous stage to prevent its further
malignant transformation.
Oral leukoplakia (OL), oral erythroleukoplakia (OEL),
and oral verrucous hyperplasia (OVH) are three common
oral precancerous lesions. Histologically, approximately
90% of OL lesions show hyperparakeratosis or hyper-
orthokeratosis and/or epithelial hyperplasia, whereas
nearly all OEL lesions reveal some degree of epithelial
dysplasia, carcinoma in situ or superficially invasive carci-
noma.4 In addition, OEL lesions have higher mitotic and
apoptotic indices than homogeneous and nodular OL
lesions.5 Immunohistochemical study also demonstrates
a higher Ki67 or p53 expression in OEL than in homogeneous
and nodular OL lesions.5 Thus, OEL has a higher malignant
transformation rate than OL.4 In Taiwan, both betel quid
chewing and cigarette smoking are involved in multistate
progression of oral precancers including OL and OEL
lesions.6,7 A cohort study found an average dwelling period
of 24 years for OL and of 7 years for OEL. Furthermore, the
risks of developing oral cancer after 20 years of follow-up
are 42.2% for OL and 95.0% for OEL.7 These findings
suggest that OEL lesions have higher malignant trans-
formation potential than OL lesions. A retrospective clinical
study showed a malignant transformation rate of 3.1% and
a mean malignant transformation duration of 54.6 months
for 324 OVH lesions of Taiwanese patients.8 Wang et al9 also
demonstrated a 5-year malignant transformation rate of 3%for 30 plaque-typed and of 17% for 30 mass-typed OVH
lesions. The high malignant transformation rates of OEL and
OVH lesions highlight the importance of early detection and
treatment of these two types of oral precancerous lesions.
Surgical treatment of OL or other oral precancerous
lesions may be performed either through conventional
surgery, electrocauterization, laser ablation, or cryosur-
gery. Recurrence of OL lesions after surgical treatment has
been reported in 10e35% of cases.10 Large oral precancerous
lesions treated by total surgical excision frequently result in
scar formation.11 Photodynamic therapy (PDT) is another
effective treatment option for human oral precancerous
lesions because it can be used repeatedly without cumula-
tive side effects, results in little or no scar formation, has
lower invasiveness, has the ability to treat multifocal
lesions, and can be applied to patients who refuse surgery or
have pacemakers and bleeding tendency.12
PDT needs two individually nontoxic components, light
and a photosensitizer, that work together to induce cellular
and tissue destruction in an oxygen-dependent manner. The
technique is based on the administration of an exogenous
photosensitizer to render tumor tissue sensitive to light of
a specific wavelength. The photosensitizers are normally
inert and have a selective affinity to premalignant and
malignant tissues. When a photosensitizer in tissues is
activated by a light of specific wavelength, it transfers
energy from light to molecular oxygen, resulting in gener-
ation of reactive oxygen species such as free radicals and
singlet oxygen.12 There are three main mechanisms by
which PDT mediates tumor destruction. Firstly, the free
radicals and singlet oxygen can kill tumor cells directly.
Secondly, PDT can damage the tumor-associated vascula-
ture, leading to thrombus formation and subsequent tumor
infarction. Thirdly, PDT-destroyed tumor tissue-released
tumor specific antigens can also activate an immune
response against the residual tumor cells.12
5-Aminolevulinic acid (ALA) itself is not a photosensitizer
but serves as the biological precursor of the photosensi-
tizer, protoporphyrin IX (PpIX), in the heme biosynthesis
pathway. When ALA is topically applied on the oral lesions
or systemically administrated by the patients, it will be
ALA-PDT for oral precancers 309absorbed by the lesional epithelial cells and results in
accumulation of relatively high concentration of PpIX in
these cells.13,14 ALA is superior to other photosensitizers
because it can be rapidly cleared from the tissues and the
body within 48 hours and patients after ALA-mediated PDT
(ALA-PDT) treatment have no problem of prolonged skin
photosensitivity.12e14
In this article, we review the previous studies evaluating
the efficacies of PDT with systemically administered ALA
(systemic ALA-PDT) or PDT with topically applied ALA
(topical ALA-PDT) on oral precancers including OL, OEL, and
OVH ,and oral cancers such as oral verrucous carcinoma and
OSCC.15e33 Previous works found that the methotrexate- or
vitamin D3-preconditioned prostate or skin carcinoma cells
can accumulate more intracellular PpIX due to the marked
augmentation of coproporphyrinogen oxidase expression
and the slight reduction of ferrochelatase expression,
resulting in an increased killing of these preconditioned
cells by subsequent ALA-PDT.34e41 Therefore, we also
review a few studies assessing the effects of methotrexate-
or vitamin D3-preconditioned ALA-PDT on killing of prostate
or skin carcinoma cells in vitro and in vivo.34e41 Because
chemotherapy can help destroy carcinoma cells or tumor-
associated vasculatures and cryotherapy pretreatment
may help the diffusion of ALA into lesional epithelial cells,
we review several studies evaluating the efficacies of
combination treatments of chemotherapy or cryotherapy
plus ALA-PDT on cancer cell lines in vitro or solid tumors
implanted in animals in vivo.42e49 Finally, the effects of
topical ALA-PDT or topical photosan-PDT on hamster buccal
pouch precancers are also reviewed.50,51Systemic ALA-PDT for oral cancers and
precancers
Systemic ALA-PDT has been used for treatment of oral
cancerous and precancerous lesions with relatively good
clinical outcomes.15,16 Grant et al15 first used PDT with
orally administered ALA to treat four patients with
advanced oral cancer. They found tumor necrosis in three
of four patients treated with PDT. Fan et al16 used systemic
ALA-PDT to treat six oral cancer and 12 oral dysplastic
lesions. They observed a reduction in the size of the cancer
in five of six patients after PDT, but only two showed
a complete regression of the cancer. In addition, all 12
dysplastic lesions showed a significant regression to normal
or less dysplastic after PDT.Topical ALA-PDT for oral cancers
An extensive buccal verrucous carcinoma which was
successfully eradicated by 28 treatments with a regular
topical ALA-PDT (fluence rate, 100 mW/cm2; light dose,
100 J/cm2) has been reported.17 Moreover, an enhanced
topical ALA-PDT protocol (fluence rate, 200 mW/cm2; light
dose, 200 J/cm2) was also used successfully to treat an
early invasive OSCC that showed complete regression after
18 PDT treatment.18 Although only two oral cancer cases
are treated with these two different topical ALA-PDT
protocols, it is suggested that if there is no concurrentregional or distant metastasis for oral verrucous carcinoma
or early invasive OSCC that is limited to the superficial
lamina propria of the oral mucosa, regular or enhanced
topical ALA-PDT may be a treatment of choice for these two
particular kinds of oral cancer.Topical ALA-PDT for oral or laryngeal
leukoplakia
Kubler et al19 treated 12 OL lesions with PDT after local
application of 20% ALA cream. Of these lesions, complete
response (CR) was found in five, partial response (PR) in
four, and no response (NR) in three. Sieron et al20,21 treated
17 OL lesions with PDT after topical application of 10% ALA
ointment or emulsion in two separate studies. CR was
observed in 14 out of 17 OL lesions. Franco22 treated 12
recalcitrant laryngeal leukoplakia lesions with PDT using
585-nm pulsed dye laser after topical application of 20%
ALA cream. He found CR in nine out of 12 laryngeal leu-
koplakia lesions.22 In addition, Shafirstein et al23 treated 17
OL lesions with topical ALA-PDT using high-power 585-nm
pulsed dye laser after placing a gauze saturated with 20%
ALA solution against the OL lesions for 1.5 hours. They
demonstrated a >75% regression (significant response) in
seven (41%) OL lesions and a >25% regression (PR) in nine
(53%) OL lesions, resulting in an overall response rate of 94%
at 90 days. In addition, three of the six OL lesions treated
with the PDT after intralesional injection of 20% ALA solu-
tion showed significant response. They found no significant
difference in PDT outcome for OL lesions treated with ALA-
PDT after either topical application or intralesional injec-
tion of 20% ALA solution.23 Jerjes et al24 used PDT with
either 5-ALA or m-tetrahydroxyphenylchlorin (mTHPC) as
the photosensitizer to treat a total of 147 consecutive
patients with oral potentially malignant disorders. The 147
patients include 55 with homogenous leukoplakia, 73 with
nonhomogenous leukoplakia, and 19 with erythroplakia.
Histopathologically, moderate dysplasia is identified in 33
patients, severe dysplasias in 63 patients; and carcinoma in
situ in 32 patients. ALA cream is applied topically 3e4 hours
prior to tissue illumination for patients with thin-mild-
moderate dysplasia, and m-THPC is administered at
a dose of 0.1 mg/kg of body weight intravenously into the
midcubital vein 96 hours before light treatment for patients
with thick mild-moderate, severe dysplasia and carcinoma
in situ. The final outcomes of the cohort show CR in 119
(81%) patients, PR in 12 (8.2%) patients, stable disease in
five (3.4%) patients, and progressive disease in 11 (7.5%)
patients. They concluded that topical ALA-PDT and
systemic mTHPC-PDT offer an effective alternative treat-
ment for oral potentially malignant disorders.24 Kawczyk-
Krupka et al25 used topical ALA-PDT to treat 48 OL
lesions. Of the 48 OL lesions, 30 were treated with PDT
using the 630-nm Diomed laser light and a topically applied
20% ALA emulsion and 18 with PDT using the 635-nm argon-
pumped dye laser light and a topically applied 10% ALA
emulsion. They found CR in 20 (67%) of the former 30 OL
lesions and in 15 (83%) of the latter 18 OL lesions. Moreover,
recurrence was observed in 11 (37%) of the former 30 OL
lesions and in two (11%) of the latter 18 OL lesions over a 6-
month period.25
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diode (LED) light was used to treat 65 OL lesions once
a week and another 32 OL lesions twice a week.26e28 Lesion
response was characterized as follows: CR, lack of detect-
able lesion confirmed by clinical evaluation; PR, reduction
of lesion by 20% in diameter; and NR, reduction of lesion
by &20% in diameter. It was found that the 65 OL lesions
treated with topical ALA-PDT once a week showed CR in
five, PR in 33, and NR in 27. The 32 OL lesions treated with
the same topical ALA-PDT twice a week demonstrate CR in
11 and PR in 21. The 32 OL lesions treated twice a week had
a significantly better clinical outcome than the 65 OL
lesions treated once a week. Furthermore, recurrence was
found in one (20%) of the five CR OL lesions treated with
PDT once a week and in two (18%) of the 11 CR OL lesions
treated with PDT twice a week.28 Although this does not
demonstrate a promising clinical outcome for OL lesions
treated with regular topical ALA-PDT, the results of other
studies do show that topical ALA-PDT is a relatively effec-
tive treatment modality for OL lesions.Topical ALA-PDT for oral verrucous hyperplasia
A regular topical ALA-PDT with the 635-nm LED light was
used to treat 36 OVH lesions once a week.26e30 It was found
that all the 36 OVH lesions show CR after an average of 3.8
(range, 1e6) treatments of topical ALA-PDT. OVH lesions
with a clinical appearance of a mass (2.9  1.3 treat-
ments), with greatest diameter <1.5 cm (3.0  1.3 treat-
ments), with the pink color (3.2  1.4 treatments), with
epithelial dysplasia (3.1  1.5 treatments), or with surface
keratin layer &40 mm (3.4  1.4 treatments) need signifi-
cantly fewer mean treatment numbers of PDT to achieve
a CR than OVH lesions with a clinical appearance of a pla-
que or a combination type (4.7  1.1 treatments), with the
greatest diameter 1.5 cm (4.3  1.4 treatments), with
the white color (4.8  1.1 treatments), without epithelial
dysplasia (4.2  1.3 treatments), or with the surface
keratin layer >40 mm (4.8  0.7 treatments), respectively.
Multivariate analyses showed that the clinical appearance
of OVH lesions is the only independent factor for prediction
of the PDT treatment number. No recurrence of the 36 OVH
lesions was found after a follow-up period of 6e56 (mean,
26) months. It is concluded that complete regression of
OVH lesions with a mean diameter of 1.7 (range, 0.5e3.1)
cm can be achieved by less than seven treatments of
topical ALA-PDT once a week. The PDT treatment outcome
for OVH depends on the clinical appearance, size, color,
epithelial dysplasia, and surface keratin thickness of the
lesion.30 In addition, an enhanced topical ALA-PDT protocol
was used successfully to treat an extensive buccal OVH
lesion that showed complete regression after 18 PDT
treatments.31
For comparison, 40 OVH lesions were treated with
topical ALA-PDT using the 635-nm laser light once a week.32
We found that all the 40 OVH lesions exhibit CR after an
average of 3.6 (range, 1e6) PDT treatments. Moreover, the
mean number of PDT treatments to achieve a CR for OVH
lesions with the clinical appearance of a mass (2.8  1.1
treatments), with greatest diameter <1.5 cm (2.2  0.7
treatments), with pink color (3.0  1.2 treatments), withepithelial dysplasia (2.5  1.1 treatments), or with surface
keratin layer 40 mm (3.0  1.2 treatments) was signifi-
cantly fewer than for OVH lesions with the clinical
appearance of a plaque or a combination type (4.4  0.8
treatments), with greatest diameter 1.5 cm (4.3  0.8
treatments), with white color (4.4  0.8 treatments),
without epithelial dysplasia (4.2  0.8 treatments), or with
surface keratin layer >40 mm (4.4  0.8 treatments),
respectively. Multivariate logistic regression analyses
showed that the size of OVH lesions was the only inde-
pendent factor influencing the PDT treatment number. No
recurrence of the 40 OVH lesions was found after a follow-
up period of 8e37 (mean, 20) months.32 In addition,
although the mean treatment number of PDT to achieve
a CR for the 40 laser light-treated OVH lesions (3.6  1.2
treatments) was lower than that for the 36 LED light-
treated OVH lesions (3.8  1.5 treatments), no significant
difference was found.30,32Topical ALA-PDT for oral erythroleukoplakia
A regular topical ALA-PDT with the 635-nm LED light has
also been used to treat 20 OEL lesions once a week.32,33 It
was found that the 20 OEL lesions treated with topical ALA-
PDT once a week show CR in 17 and PR in three. In addition,
the 17 CR OEL lesions needed an average of 3.7 (range,
2e7) treatments of ALA-PDT to achieve CR of the lesions.
Correlation analyses revealed that the mean number of PDT
treatments needed to achieve a CR for OEL lesions with
greatest diameter <1.5 cm (3.0  0.9 treatments) or with
surface keratin layer 30 mm (2.9  0.9 treatments) was
significantly fewer than for OEL lesions with greatest
diameter 1.5 cm (4.5  1.5 treatments) or with surface
keratin layer >30 mm (4.6  1.3 treatments), respectively.
After a follow-up period of 16e76 (mean, 32) months, five
(29%) of the 17 CR OEL lesions recurred. These five lesions
recur 8-14 (mean, 11) months after the last PDT treatment.
The five recurrent lesions were treated by the same PDT
protocol as before and showed complete regression after
2e4 (mean, 2.8) treatments.33
For comparison, 40 OEL lesions were treated with topical
ALA-PDT using the 635-nm laser light once a week.32 Of the
40 OEL lesions, 38 showed CR after an average of 3.4
(range, 2e6) PDT treatments and 2 showed PR. It was found
that the mean number of PDT treatments needed to ach-
ieve a CR for OEL lesions with greatest diameter <1.5 cm
(2.7  1.0 treatments) or with surface keratin layer 30 mm
(2.7  0.9 treatments) was significantly fewer than for OEL
lesions with greatest diameter S1.5 cm (4.4  1.3 treat-
ments) or with surface keratin layer >30 mm (4.5  1.2
treatments), respectively. After a follow-up period of 6e30
(mean, 18) months, eight (21%) of the 38 CR OEL lesions
recurred. These eight OEL lesions recurred 6e14 (mean, 9)
months after the last PDT treatment. The eight OEL
recurrent lesions were treated by the same PDT protocol as
before and show complete regression after 1e3 (mean, 2)
treatments.32 Although the mean number of PDT treat-
ments to achieve a CR for the 38 laser light-treated OEL
lesions (3.4  1.4) was lower than that for the 17 LED light-
treated OEL lesions (3.7  1.4), no significant difference
was found.32,33
ALA-PDT for oral precancers 311Why is topical ALA-PDT very effective for OVH
and OEL lesions but less effective for OL
lesions?
Previous studies have found that topical ALA-PDT is very
effective for OVH and OEL lesions but less so for OL
lesions.26e33 We suggest that the successful clinical
outcomes for OVH and OEL lesions treated by either the LED
or laser light-mediated topical ALA-PDT may be due to the
ALA preparation, the topical ALA-PDT protocol used, and
the characteristic morphological, histologic, and biological
features of the OVH and OEL lesions themselves. In brief,
the 20% ALA preparation is a gel form, which is adhesive to
the oral mucosa, is partially resistant to the dilution of the
saliva, and in turn helps the absorption of ALA from the
mucosal surface. Moreover, the studies used a fractionated
protocol to deliver light treatment (repeated cycles of 3-
minute light illumination followed by 3-minute rest); the
lesional epithelial cells might regenerate new PpIX and
obtain new oxygen during multiple 3-minute resting
periods, finally resulting in a more successful clinical
outcome for our OVH and OEL lesions.26e33
The verrucous appearance of the OVH lesion provides
a large area for good retention and absorption of ALA on the
surface. In general, OVH and OEL lesions with smaller size,
pink to red color, epithelial dysplasia, and thinner surface
keratin layer have better PDT outcomes than those corre-
sponding lesions, respectively. Pink to red and dysplastic
oral OVH and OEL lesions usually have thinner surface
keratin layer, leading to diffusion of more ALA into the
lesional epithelial cells. Furthermore, dysplastic OVH and
OEL lesions usually have a more permeable epithelium (due
to wide intercellular spaces of the dysplastic epithelium);
this also results in diffusion of more ALA into the lesional
epithelial cells. In addition, dysplastic epithelium may
retain more ALA than hyperplastic epithelium, and the
thinner surface keratin layer may only have a minimal
effect on the reduction of the light intensity. In addition,
there are more epithelial cells in the cell division cycle in
dysplastic OVH and OEL lesions than in nondysplastic OVH
lesions.52 Dysplastic epithelial cells in the cell division cycle
are more susceptible to destruction by PDT-generated
singlet oxygen molecules and free radicals than those
epithelial cells not in the cell division cycle. Sufficient
photosensitizers and light dose finally result in a better
clinical outcome for those OVH and OEL lesions with pink to
red color, epithelial dysplasia, and thinner surface keratin
layer.26e33
Furthermore, mass-typed OVH lesions are highly protu-
berant and are usually situated on a smaller base area than
plaque-typed or combination-typed OVH lesions. In our
experience, the purely mass-typed lesions or the central
masses of combination-typed lesions usually show complete
regression after oneor two treatments of PDT. In contrast, the
purely plaque-typed lesions or the residual peripheral plaques
of combination-typed lesions may need more PDT treatments
to achieve a CR. Because PDT can damage the tumor-
associated vasculature and mass-typed OVH lesions with
a smaller base area usually have limited blood supply, these
mass-typedOVHlesionsareeasilyeradicatedbyPDT,probably
through a combined mechanism of reactive oxygen species-mediated tumor cell killing and endothelial cell destruction
followed by thrombus formation and tumor infarction.12,30
LED versus laser light sources for ALA-PDT
To the best of our knowledge, most of the previous ALA-PDT
studies used laser light to treat a variety of premalignant
and malignant human lesions; we first tested the efficacy of
an LED light-mediated ALA-PDT on oral premalignant lesions
such as OVH, OEL, and OL.26e31 Laser machines can provide
light with specific mono-wavelength; the laser system is
well designed, more stable, and power adjustable. It can be
used for a long period of several years without the need of
changing the laser light source. However, it is heavier, more
bulky, and more expensive. An LED light device can only
provide light with a range of wavelengths but has the
advantages of being a simpler, smaller, lighter, less
expensive, and more portable light source than the laser
machine. However, the LED chips are very sensitive to the
heat generated during the PDT treatment and may deteri-
orate rather quickly after repeated use. This results in the
need of frequent changes of the LED chips every 6e12
months. Therefore, the choice of using either the LED or
laser light source depends on the budget of the institute.
Our previous studies showed that the LED light-mediated
topical ALA-PDT is as effective as the laser light-mediated
topical ALA-PDT for treatment of OVH and OEL
lesions.32,33 This finding suggests that the total light dose
rather than the light source is more important for
a successful PDT outcome.
Systemic ALA-PDT versus topical ALA-PDT
Although both topical and systemic ALA-PDT remedies are
used for treatment of oral precancerous lesions, topical ALA-
PDT is even superior to systemic ALA-PDT because the former
uses a small amount of ALA (20e200 mg) per treatment and
has no skin photosensitivity even within the initial 48 hours
after PDT.26e33 Topical ALA-PDT is conservative and nonin-
vasive, is easily accepted by patients, and usually results in
little or no scar formation. Nevertheless, systemic ALA-PDT
uses a large dose of ALA (60 mg/kg of body weight) and
systemic administration of ALA to the patients has the side
effects of nausea, vomiting, and elevation of blood levels of
bilirubin and liver enzymes (e.g. aspartate transaminase).16
In contrast, direct topical application of ALA onto oral lesions
does not have any systemic side effects.53e55 Therefore, we
suggest the use of topical ALA-PDTas the first-line treatment
of choice for human oral precancerous lesions, especially for
both OVH and OEL lesions, in the near future.
Drug-preconditioned ALA-PDT
The efficacy of ALA-PDT depends on the amount of PpIX
accumulated in the lesional epithelial or cancer cells. PpIX
is the seventh product in the heme biosynthesis pathway.
The increase in the expression of coproporphyrinogen
oxidase (the enzyme that is responsible for the sixth step in
heme production, converting coproporphyrinogen III into
protoporphyrinogen IX) and the decrease in the expression
312 H.-M. Chen et alof ferrochelatase (the enzyme that catalyses the terminal
or eighth step in the biosynthesis of heme, converting PpIX
into heme) are responsible for the increased accumulation
of PpIX in lesional epithelial or cancer cells.56,57 Previous
studies have shown that agents capable of inducing cellular
differentiation can also cause an elevation in the level of
PpIX in prostate cancer cells and skin epithelial cells.34,35
Because methotrexate can promote differentiation and
PpIX accumulation in carcinoma cells, methotrexate may
serve as a drug to augment the efficacy of ALA-PDT for
tumor cell killing. Sinha et al36 studied methotrexate-
pretreated ALA-PDT for killing of prostate cancer cells.
They found that prostate cancer cells pretreated by
methotrexate and followed by ALA incubation can result in
a threefold increase in intracellular PpIX level, which is due
to the threefold augmentation in expression of cop-
roporphyrinogen oxidase by methotrexate. Transfection of
prostate cancer cells with a coproporphyrinogen oxidase-
expressing vector also stimulates the accumulation of
PpIX in cells. In addition, after exposure to 512-nm light,
killing is significantly enhanced in methotrexate-
preconditioned cells. These findings suggest that metho-
trexate, when used to modulate intracellular production of
endogenous PpIX, may provide a new combination PDT
approach for certain cancers.36 Recent studies also
demonstrated that low-dose methotrexate can enhance
ALA-PDT in skin carcinoma cells in vitro and in vivo.37e39
Methotrexate preconditioning of monolayer cultures can
preferentially augment intracellular PpIX levels two- to
fourfold in carcinoma cells versus normal keratinocytes.
Photodynamic killing is synergistically enhanced by the
methotrexate-combined therapy compared to PDT alone.
Methotrexate enhancement of PpIX levels is achieved
over a broad methotrexate concentration range
(0.0003e1.0 mg/L; 0.6 nMe2 mM). PpIX enhancement
correlates with a fourfold increase in expression of cop-
roporphyrinogen oxidase and no change or a slight decrease
in expression of ferrochelatase. In vivo relevance is also
established by demonstrating that methotrexate-
preconditioning enhances PpIX accumulation in three
models: organotypic cultures of immortalized keratino-
cytes, chemically induced skin tumors in mice, and human
A431 squamous cell tumors implanted subcutaneously in
mice.37 Therefore, combination therapy using short-term
exposure to low-dose methotrexate followed by ALA-PDT
should be further investigated as a new combination
treatment modality to increase the efficacy of ALA-PDT on
epithelial carcinomas.34e39
Methotrexate is chosen as an attractive candidate agent
because it is already used widely in the clinical arena, has
relatively low toxicity, and exerts its own antitumor effects
by inhibiting proliferation, promoting apoptosis, and
promoting terminal differentiation.58 The ability to
promote differentiation, in particular, suggests the idea of
using methotrexate in combination with ALA-PDT. Andro-
gens and vitamin D are also known to promote cellular
differentiation and at the same time to enhance PpIX
accumulation in prostate cancer cells.34 Sato et al40 eval-
uated the vitamin D-enhanced PpIX production and photo-
dynamic cell death in 3D organotypic cultures of
keratinocytes. They found that PpIX levels, at 4 hours after
addition of ALA (1 mM), are significantly increased invitamin D-preconditioned cultures. Maximal PpIX induction
is seen at the vitamin D concentration of 1012e1010M.
Phototoxic cell killing after exposure to 635-nm light is
significantly increased in vitamin D-preconditioned
cultures. Therefore, vitamin D may also be useful as a bio-
logical enhancer of ALA-PDT.40 Recently, Anand et al41
showed that calcitriol, delivered topically or intraperito-
neally, can raise tumoral accumulation of the PpIX up to
10-fold, mainly due to the augmentation of coproporphyri-
nogen oxidase expression and the reduction of ferrochela-
tase expression. Calcitriol-pretreated tumors undergo
enhanced apoptotic cell death after ALA-PDT. Mechanistic
studies have shown the activation of the extrinsic apoptotic
pathway, with specific cleavage of caspase-8 and increased
production of tumor necrosis factor-a in tumors treated
with the calcitriol-preconditioned ALA-PDT. Very low doses
of calcitriol (0.1e1 mg/kg body weight) are sufficient to
elicit tumor-selective enhancement to ALA-PDT efficacy.
The aforementioned findings suggest that methotrexate or
calcitriol is a simple, nontoxic, and highly effective pre-
conditioning agent to enhance the response of epithelial
tumors to ALA-PDT.34e41 To the best of our knowledge, to
date there has been no human clinical trial testing the
methotrexate- or calcitriol-preconditioned topical ALA-PDT
for oral precancers or cancers.Combination therapy of chemotherapy plus
ALA-PDT
Because chemotherapy can help destroy carcinoma cells
and tumor-associated vasculatures, previous studies also
tested whether the combination therapy of chemotherapy
plus ALA-PDT are more effective than the ALA-PDT alone. It
was found that low doses of doxorubicin and vincristine can
increase the anti-cancer effect of ALA-PDT in murine
leukemic cell lines.42 Decrease in cell survival is higher
when the combination therapy of vincristine plus ALA-PDT
is used compared to that of doxorubicin plus ALA-PDT. In
addition, doxorubicin and vincristine chemoresistant LBR-
D160 and LBR-V160 cell lines are also found to be sensi-
tive to ALA-PDT alone, although the combination therapy
does not augment its efficacy on chemoresistant cell
lines.42
Vadimezan (5,6-dimethylxanthenone-4-acetic acid),
a tumor vascular-disrupting agent, has shown to have anti-
vascular effects in both murine and human tumors via
increasing vascular permeability and hemorrhagic
necrosis.43,44 The local synthesis of cytokine TNF-a in
murine tumors is found in part to cause the tumor destruc-
tion.45,46 Previous studies have shown that addition of
intraperitoneal vadimezan to PDT using the systemically
administered photosensitizers porfimer sodium (Photofrin)
and 2-(1 -hexyloxyethyl)-2-devinyl pyropheophorbide-
a (HPPH; Photochlor) dramatically enhances the destruc-
tion of solid tumors implanted in mice.45,47 In addition,
Marrero et al48 treated Colon26 tumors implanted in mice
with either combination therapy of topical ALA-PDT (80 J/
cm2 delivered at 75mW/cm2) plus vadimezan or topical ALA-
PDT alone. For the combination therapy, 20% ALA solution
and vadimezan solution (1 mg vadimezan dissolved in 40 mL
of dimethyl sulfoxide) are topically applied onto the tumor
ALA-PDT for oral precancers 3133 hours and 1 hour prior to light treatment, respectively. It
was found that the combination therapy causes a substantial
decrease in tumor blood flow up to 2 hours following light
delivery and a significant decrease in tumor weight at the
endpoint (tumor growth of controls to 400 mL).48 The
combination therapy of chemotherapy plus ALA-PDT has not
been tested for human oral cancers and precancers.Combination therapy of cryotherapy plus
topical ALA-PDT
Mi et al49 used the combination therapy of cryotherapy plus
topical ALA-PDT and cryotherapy alone to treat 80 patients
with multiple condylomata acuminata. For the combination
therapy, the condylomata acuminata lesions were pre-
treated with cryotherapy and then a 20% ALA is applied to
the condylomata acuminata lesions 3 hours before illumi-
nation with the 635-nm red light (100 mW/cm2 and 100 J/
cm2). The lesions were treated once a week. They found
that after two treatments, the CR rates in the combination
therapy group (cryotherapy plus topical ALA-PDT) and
cryotherapy alone group were 32.4% (36/111) and 32.6%
(43/132) in the anal area, 100% (32/32) and 54.5% (18/33) in
the urethral meatus, and 94.2% (129/137) and 50.5% (56/
111) in the external genitals, respectively. The recurrence
rates in the combination therapy group and cryotherapy
alone group were 24.3% (27/111) and 31.1% (41/132) in the
anal area, 9.4% (3/32) and 39.4% (13/33) in the urethral
meatus, and 3.6% (5/137) and 31.5% (35/111) in the
external genitals, respectively. They concluded that the
combination therapy of cryotherapy plus topical ALA-PDT is
a more effective regimen for the treatment of multiple
condylomata acuminata compared to cryotherapy alone.49
A previous study has shown that topical ALA-PDT and
cryotherapy are comparative methods for treatment of OL
lesions.25 However, so far, there has been no human clinical
trial evaluating the efficacy of the combination therapy of
cryotherapy plus topical ALA-PDT on oral precancers or
cancers.Topical ALA-PDT for hamster buccal pouch
precancers
Hsu et al50 used 7,12-dimethylbenz(a)anthracene (DMBA)-
induced hamster buccal pouch carcinogenesis model to
produce 20 precancerous lesions, which were treated by
topical ALA-PDT with either a light dose of 75 J/cm2
(nZ 10) or 100 J/cm2 (nZ 10) using the 640-nm LED light.
They found that the 10 precancerous lesions treated by 75-J
topical ALA-PDT showed CR in eight after an average of 3.4
(range, 2e6) treatments and PR in two. The 10 precan-
cerous lesions treated by 100-J topical ALA-PDT demon-
strated CR in seven after an average of 4.4 (range, 3e6)
treatments and PR in three. Fisher’s exact test showed no
significant difference in clinical outcome between these
two treatment modalities. These findings indicate that both
the 75-J and 100-J topical ALA-PDT treatment modalities
are very effective for DMBA-induced hamster buccal pouch
precancerous lesions and no significant difference in PDT
outcome is found between these two treatment modalities.Photosan, a mixture of porphyrin oligomers, is intracel-
lularly converted into the active photosensitizer, PpIX, in
epithelial cells.59 For comparison, topical photosan-
mediated PDT (topical photosan-PDT) was used to treat
14 DMBA-induced hamster buccal pouch precancerous
lesions using the 640-nm LED light twice a week. It was
found that all the 14 precancerous lesions showed a CR
after an average of 3.8 (range, 3e5) PDT treatments. Our
findings indicate that topical photosan-PDT is also a very
effective treatment modality for DMBA-induced hamster
buccal pouch precancerous lesions compared to topical
ALA-PDT.50,51
Topical ALA-PDT using either the LED or laser light is
very effective for OVH and OEL lesions but is relatively
less effective for OL lesions. Better PDT outcomes are
significantly associated with OVH and OEL lesions with
smaller size, pink to red color, epithelial dysplasia, or
thinner surface keratin layer. Moreover, the thicker
surface keratin layer on the OL lesions is responsible for
the relatively poorer PDT outcomes for OL lesions.
Therefore, topical ALA-PDT using either the LED or laser
light may serve as the first-line treatment of choice for
OVH and OEL lesions. Furthermore, if oral verrucous
carcinoma or early-invasive OSCC has no concurrent
regional or distant metastasis, a regular topical ALA-PDT
(fluence rate, 100 mW/cm2; light dose, 100 J/cm2) or an
enhanced topical ALA-PDT (fluence rate, 200 mW/cm2;
light dose, 200 J/cm2) may have a high potential to treat
these two particular kinds of oral cancers. A large-scale
human clinical trial is needed to evaluate the efficacies
of drug-preconditioned topical ALA-PDT and chemo-
therapy or cryotherapy-combined topical ALA-PDT on oral
precancers, oral verrucous carcinoma, and early-invasive
OSCC in the near future.References
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